Bruce A Pfeffer

US Patent:

20020142362, Oct 3, 2002

Filed:

May 23, 2000

Appl. No.:

09/576501

Inventors:

Rosemarie Flick - Copiague NY, US
Bruce Pfeffer - Valley Cottage NY, US
Naveed Shams - Duluth GA, US
Stephen Bartels - Wyckoff NJ, US

International Classification:

C12Q001/37

US Classification:

435/023000, 435/125000

Abstract:

A calorimetric assay system to measure the expression or activity of membrane-type matrix metalloproteinases using a thiopeptolide substrate. The subject colorimetric assay system is useful in screening pharmacological agents that may have therapeutic potential in the treatment of glaucoma and the promotion of wound healing. The subject colorimetric assay system is also useful in the discovery of new therapies for cancer and conditions involving neovascularization based on modulation of extracellular matrix.

US Patent:

20040068017, Apr 8, 2004

Filed:

Sep 27, 2002

Appl. No.:

10/260448

Inventors:

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Copiaque NY, US
Naveed Shams - Duluth GA, US
Stephen Bartels - Pittsford NY, US

International Classification:

A61K031/155
C07C281/18

US Classification:

514/632000, 564/228000

Abstract:

Small organic molecules capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

US Patent:

20060121090, Jun 8, 2006

Filed:

Jan 20, 2006

Appl. No.:

11/336536

Inventors:

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Copiaque NY, US
Naveed Shams - Duluth GA, US
Stephen Bartels - Pittsford NY, US

International Classification:

A61K 31/47
A61K 31/445
A61K 31/426
A61K 31/405
A61K 31/381
A61K 31/4172
A61K 31/325

US Classification:

424427000, 514478000, 514317000, 514319000, 514370000, 514313000, 514400000, 514405000, 514448000

Abstract:

Compositions capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

US Patent:

20070049559, Mar 1, 2007

Filed:

Jun 28, 2006

Appl. No.:

11/476496

Inventors:

Bruce Pfeffer - Fairport NY, US
Rosemarie Flick - Collegeville PA, US
Stephen Bartels - Pittsford NY, US

International Classification:

A61K 31/655
A61K 31/517
A61K 31/498
A61K 31/47

US Classification:

514150000, 514249000, 514266100, 514310000, 514311000, 514248000

Abstract:

Preparations for controlling intraocular pressure in the eye comprise as an active compound, arylazine substituted with a carbonylic moiety, which compound is capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork to promote outflow of aqueous. The organic active compound increases Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for glaucoma, e.g., primary open angle glaucoma.

US Patent:

20070134230, Jun 14, 2007

Filed:

Dec 6, 2006

Appl. No.:

11/567338

Inventors:

Dharmendra Jani - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Michael Hartzer - Arlington TX, US

International Classification:

A61K 38/48
C12N 9/64

US Classification:

424094630, 435226000

Abstract:

A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a pH less than about 5, and reconstituting the acidified enzyme substantially immediately before use with a buffer having a pH in the range from about 6.5 to about 11, wherein the pH remains within 1 pH unit upon adding said the enzyme into the buffer. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

US Patent:

20070134231, Jun 14, 2007

Filed:

Nov 17, 2006

Appl. No.:

11/601389

Inventors:

Dharmendra Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory McIntire - Rochester NY, US
Bruce Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen Davio - Fair Port NY, US

International Classification:

A61K 38/48
A61K 31/198

US Classification:

424094640, 514566000

Abstract:

A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

US Patent:

20100104551, Apr 29, 2010

Filed:

Oct 22, 2009

Appl. No.:

12/603988

Inventors:

Dharmendra M. Jani - Fairport NY, US
Kai Kwok - Rochester NY, US
Gregory L. McIntire - Rochester NY, US
Bruce A. Pfeffer - Fairport NY, US
Afshin Shafiee - Rochester NY, US
Ruiwen Shi - Cupertino CA, US
Srini Venkatesh - Pittsford NY, US
Hongna Wang - Fairport NY, US
Yan Huang - Webster NY, US
Stephen R. Davio - Fairport NY, US

Assignee:

Talecris Biotherapeutics, Inc. - Research Triangle Park NC

International Classification:

A61K 38/48
A61P 27/02

US Classification:

424 9464

Abstract:

A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.

US Patent:

20110077270, Mar 31, 2011

Filed:

Mar 26, 2010

Appl. No.:

12/732460

Inventors:

Bruce A. Pfeffer - Fairport NY, US
Charu A. DeWitt - Pittsford NY, US
Keith W. Ward - Ontario NY, US
Francisco J. Lopez - Victor NY, US

International Classification:

A61K 31/4709
A61P 29/00
A61P 27/02
A61P 3/10

US Classification:

514313

Abstract:

A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in an affected eye to treat or control the ocular inflammatory disease or condition.